Evidence map›Paper›PMID 35489095›Full record

ArticleTalanta2022

Equipment-free, gold nanoparticle based semiquantitative assay of SARS-CoV-2-S1RBD IgG from fingertip blood: A practical strategy for on-site measurement of COVID-19 antibodies.

Zhitong Zhu, Xiaoming Ma, Lin Zhu, Qiong Luo, Nan Lin, Zhonghui Chen, Xingchen Zhao, Zhenyu Lin, Zongwei Cai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Talanta, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhitong ZhuState Key Laboratory of Environmental and Biological Analysis, Hong Kong Baptist University, Hong Kong, China.
Xiaoming MaKey Laboratory of Organo-Pharmaceutical Chemistry of Jiangxi Province, School of Chemistry and Chemical Engineering, Gannan Normal University, Ganzhou, 341000, PR China.
Lin ZhuState Key Laboratory of Environmental and Biological Analysis, Hong Kong Baptist University, Hong Kong, China. Electronic address: zhu_lin@hkbu.edu.hk.
Qiong LuoState Key Laboratory of Environmental and Biological Analysis, Hong Kong Baptist University, Hong Kong, China.
Nan LinState Key Laboratory of Environmental and Biological Analysis, Hong Kong Baptist University, Hong Kong, China.
Zhonghui ChenAffiliated Hospital of Putian University, Putian University, Putian, 351100, China.
Xingchen ZhaoState Key Laboratory of Environmental and Biological Analysis, Hong Kong Baptist University, Hong Kong, China.
Zhenyu LinMinistry of Education Key Laboratory for Analytical Science of Food Safety and Biology, Fujian Provincial Key Laboratory of Analysis and Detection for Food Safety, Department of Chemistry, Fuzhou University, Fuzhou, 350116, China.
Zongwei CaiState Key Laboratory of Environmental and Biological Analysis, Hong Kong Baptist University, Hong Kong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 remains as a major threat to human society. A reliable, sensitive, rapid, and low requirement assay for serum neutralizing antibodies is needed as a pandemic management tool for estimation of revaccination time and implementation of "immune passport". Using gold nanoparticle (AuNR) as an immunosensor, we have established a semi-quantitative, instrument-free assay for measuring antibody level against SRAS-CoV-2 spike1 (S1) receptor binding domain (RBD) from fingertip blood samples. The testing results by the developed method correlated well with those obtained from conventional ELISA assay, indicating reliable quantitation could be achieved without use of plate reader. A declined of immunoglobulin G (IgG) antibody associated with vaccination time was observed, which agreed well with the data from other reports. The developed method provides a potentially complementary strategy for on-site measurement of COVID-19 antibodies.

Indexed as

Biosensing TechniquesCOVID-19Metal NanoparticlesAntibodies, ViralGoldHumansImmunoassayImmunoglobulin GSARS-CoV-2Antibodies, ViralGoldImmunoglobulin GAuNRColorimetric reagentFingertip bloodIgG antibodySARS-CoV-2

Identifiers

PMID35489095
PMCPMC9040429

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.